<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37340981</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1525-6049</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Renal failure</Title><ISOAbbreviation>Ren Fail</ISOAbbreviation></Journal><ArticleTitle>Expression of interferon-stimulated gene 20 (ISG20), an antiviral effector protein, in glomerular endothelial cells: possible involvement of ISG20 in lupus nephritis.</ArticleTitle><Pagination><StartPage>2224890</StartPage><MedlinePgn>2224890</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2224890</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2023.2224890</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">In addition to regulating the antiviral response, increased expression of Toll-like receptor 3 (TLR3) in resident renal cells plays a role in developing some forms of glomerulonephritis. TLR3 activation leads to type I interferon (IFN) production, which induces the expression of IFN-stimulated genes (ISGs). However, the role of ISG20 expression in resident renal cells remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Cultured normal human glomerular endothelial cells (GECs) were treated with polyinosinic-polycytidylic acid (poly IC), <i>Escherichia coli</i> lipopolysaccharide (LPS), R848, and CpG (TLR3, TLR4, TLR7, and TLR9 agonists, respectively). The mRNA levels of ISG20, CX3CL1/fractalkine, and CXCL10/IP-10 were measured by quantitative reverse transcription-polymerase chain reaction. ISG20 protein expression was assessed by Western blotting. RNA interference was used to knockdown IFN-&#x3b2; and ISG20 expression. CX3CL1 protein levels were assessed by enzyme-linked immunosorbent assay. We performed immunofluorescence to examine endothelial ISG20 expression in biopsy specimens from patients with lupus nephritis (LN).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In GECs, the expression of ISG20 mRNA and protein was increased by polyIC, not by LPS, R848, or CpG treatment. Moreover, ISG20 knockdown prevented poly IC-induced CX3CL1 expression but had no effect on CXCL10 expression. Intense endothelial ISG20 immunoreactivity was observed in biopsy specimens obtained from patients with proliferative LN.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In GECs, ISG20 was regulated <i>via</i> TLR3 but not <i>via</i> TLR4, TLR7, or TLR9 signaling. Moreover, ISG20 was involved in regulating CX3CL1 production. In addition to regulating antiviral innate immunity, ISG20 may act as a mediator of CX3CL1 production, thereby inducing glomerular inflammation, particularly in patients with LN.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karasawa</LastName><ForeName>Takao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Riko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Tadaatsu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aizawa</LastName><ForeName>Tomomi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsugawa</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattinzoli</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Renal Research Laboratory, Fondazione D'Amico per la Ricerca sulle Malattie Renali &amp; Fondazione IRCCS Ca', Granda Ospedale Maggiore Policlinico, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawaguchi</LastName><ForeName>Shogo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seya</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terui</LastName><ForeName>Kiminori</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joh</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Jikei Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Aomori, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of School Health Science, Hirosaki University, Hirosaki, Aomori Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ren Fail</MedlineTA><NlmUniqueID>8701128</NlmUniqueID><ISSNLinking>0886-022X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090103">Antiviral Restriction Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="C112346">ISG20 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>O84C90HH2L</RegistryNumber><NameOfSubstance UI="D011070">Poly I-C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051196">Toll-Like Receptor 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051199">Toll-Like Receptor 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051217">Toll-Like Receptor 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D005095">Exoribonucleases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090103" MajorTopicYN="N">Antiviral Restriction Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050527" MajorTopicYN="N">Mesangial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011070" MajorTopicYN="N">Poly I-C</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051196" MajorTopicYN="N">Toll-Like Receptor 3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051199" MajorTopicYN="N">Toll-Like Receptor 7</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051217" MajorTopicYN="N">Toll-Like Receptor 9</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005095" MajorTopicYN="Y">Exoribonucleases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CX3CL1</Keyword><Keyword MajorTopicYN="N">glomerular endothelial cells</Keyword><Keyword MajorTopicYN="N">interferon-stimulated gene 20</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">toll-like receptor 3</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37340981</ArticleId><ArticleId IdType="pmc">PMC10286675</ArticleId><ArticleId IdType="doi">10.1080/0886022X.2023.2224890</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lai AS, Lai KN.. Viral nephropathy. Nat Clin Pract Nephrol. 2006;2(5):1&#x2013;8. doi: 10.1038/ncpneph0166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpneph0166</ArticleId><ArticleId IdType="pmc">PMC7097026</ArticleId><ArticleId IdType="pubmed">16932438</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Banas B, Schl&#xf6;ndorff D.. Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol. 2004;15(4):854&#x2013;867. doi: 10.1097/01.asn.0000121781.89599.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.asn.0000121781.89599.16</ArticleId><ArticleId IdType="pubmed">15034087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepe V, Libetta C, Gregorini M, et al. . The innate immune system in human kidney inflammaging. J Nephrol. 2022;35(2):381&#x2013;395. doi: 10.1007/s40620-021-01153-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-021-01153-4</ArticleId><ArticleId IdType="pmc">PMC8617550</ArticleId><ArticleId IdType="pubmed">34826123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto S, Nakatani K, Iwano M, et al. . Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis. 2007;50(1):47&#x2013;58. doi: 10.1053/j.ajkd.2007.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2007.04.012</ArticleId><ArticleId IdType="pubmed">17591524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono K, Imaizumi T, Aizawa T, et al. . Endothelial expression of fractalkine (CX3CL1) is induced by toll-like receptor 3 signaling in cultured human glomerular endothelial cells. Mod Rheumatol. 2020;30(6):1074&#x2013;1081. doi: 10.1080/14397595.2019.1682768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2019.1682768</ArticleId><ArticleId IdType="pubmed">31625434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, Ren Y, He X.. IFN-I mediates lupus nephritis from the beginning to renal fibrosis. Front Immunol. 2021;12:676082. doi: 10.3389/fimmu.2021.676082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676082</ArticleId><ArticleId IdType="pmc">PMC8093624</ArticleId><ArticleId IdType="pubmed">33959133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T, Akira S.. TLR signaling. Cell Death Differ. 2006;13(5):816&#x2013;825. doi: 10.1038/sj.cdd.4401850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401850</ArticleId><ArticleId IdType="pubmed">16410796</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HS. Pseudoviral immunity - a novel concept for lupus. Trends Mol Med. 2009;15(12):553&#x2013;561. doi: 10.1016/j.molmed.2009.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2009.10.004</ArticleId><ArticleId IdType="pubmed">19896418</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Imaizumi T.. Inflammatory chemokine expression via toll-like receptor 3 signaling in normal human mesangial cells. Clin Dev Immunol. 2013;2013:984708. doi: 10.1155/2013/984708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/984708</ArticleId><ArticleId IdType="pmc">PMC3710592</ArticleId><ArticleId IdType="pubmed">23935652</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Imaizumi T, Tsuruga K, et al. . Glomerular expression of myxovirus resistance protein 1 (Mx1) in human mesangial cells: possible activation of innate immunity in the pathogenesis of lupus nephritis. Nephrology (Carlton). 2013;18(12):833&#x2013;837. doi: 10.1111/nep.12155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.12155</ArticleId><ArticleId IdType="pubmed">24674141</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi T, Aizawa T, Segawa C, et al. . Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1, in human mesangial cells. Clin Exp Nephrol. 2015;19(5):761&#x2013;770. doi: 10.1007/s10157-014-1060-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-014-1060-4</ArticleId><ArticleId IdType="pubmed">25471749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz G, Lech M, Anders HJ.. Toll-like receptor activation in the pathogenesis of lupus nephritis. Clin Immunol. 2017;185:86&#x2013;94. doi: 10.1016/j.clim.2016.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.07.015</ArticleId><ArticleId IdType="pubmed">27423476</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti F, Spinelli FR, Truglia S, et al. . Kidney expression of toll-like receptors in lupus nephritis: quantification and clinicopathological correlations. Mediators Inflamm. 2016;2016:7697592. doi: 10.1155/2016/7697592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/7697592</ArticleId><ArticleId IdType="pmc">PMC5011205</ArticleId><ArticleId IdType="pubmed">27635115</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi T, Yano C, Numata A, et al. . Interferon (IFN)-induced protein 35 (IFI35), a type I interferon-dependent transcript, upregulates inflammatory signaling pathways by activating toll-like receptor 3 in human mesangial cells. Kidney Blood Press Res. 2016;41(5):635&#x2013;642. doi: 10.1159/000447932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000447932</ArticleId><ArticleId IdType="pubmed">27639618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto S, Imaizumi T, Aizawa T, et al. . Expression of IFN-induced transmembrane protein 1 in glomerular endothelial cells. Pediatr Int. 2021;63(9):1075&#x2013;1081. doi: 10.1111/ped.14579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ped.14579</ArticleId><ArticleId IdType="pubmed">33332692</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasawa T, Sato R, Imaizumi T, et al. . Glomerular endothelial expression of type I IFN-stimulated gene, DExD/H-Box helicase 60 via toll-like receptor 3 signaling: possible involvement in the pathogenesis of lupus nephritis. Ren Fail. 2022;44(1):137&#x2013;145. doi: 10.1080/0886022X.2022.2027249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2022.2027249</ArticleId><ArticleId IdType="pmc">PMC9004514</ArticleId><ArticleId IdType="pubmed">35392757</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosse KM, Monson EA, Beard MR, et al. . Interferon-stimulated genes as enhancers of antiviral signaling. J Innate Immun. 2018;10(2):85&#x2013;93. doi: 10.1159/000484258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000484258</ArticleId><ArticleId IdType="pmc">PMC5969054</ArticleId><ArticleId IdType="pubmed">29186718</ArticleId></ArticleIdList></Reference><Reference><Citation>Espert L, Degols G, Gongora C, et al. . ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA. J Biol Chem. 2003;278(18):16151&#x2013;16158. doi: 10.1074/jbc.M209628200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M209628200</ArticleId><ArticleId IdType="pubmed">12594219</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi T, Shimada T, Matsumiya T, et al. . Interferon-stimulated gene 15, a type I interferon-dependent transcript, is involved in a negative feedback loop in innate immune reactions in human mesangial cells. Nephron. 2016;132(2):144&#x2013;152. doi: 10.1159/000443934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000443934</ArticleId><ArticleId IdType="pubmed">26844778</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi T, Tanaka H, Mechti N, et al. . Polyinosinic-polycytidylic acid induces the expression of interferon-stimulated gene 20 in mesangial cells. Nephron Exp Nephrol. 2011;119(2):e40&#x2013;e48. doi: 10.1159/000328923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000328923</ArticleId><ArticleId IdType="pubmed">21832855</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa-Yashiro T, Imaizumi T, Tsuruga K, et al. . Glomerular expression of fractalkine is induced by polyinosinic-polycytidylic acid in human mesangial cells: possible involvement of fractalkine after viral infection. Pediatr Res. 2013;73(2):180&#x2013;186. doi: 10.1038/pr.2012.165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/pr.2012.165</ArticleId><ArticleId IdType="pubmed">23168573</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Vielhauer V, Schl&#xf6;ndorff D.. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 2003;63(2):401&#x2013;415. doi: 10.1046/j.1523-1755.2003.00750.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2003.00750.x</ArticleId><ArticleId IdType="pubmed">12631106</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss CM, Trobaugh DW, Sun C, et al. . The interferon-induced exonuclease ISG20 exerts antiviral activity through upregulation of type I interferon response proteins. mSphere. 2018;3(5):e00209&#x2013;e00218. doi: 10.1128/mSphere.00209-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00209-18</ArticleId><ArticleId IdType="pmc">PMC6147134</ArticleId><ArticleId IdType="pubmed">30232164</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M, Lin Y, Liu X, et al. . ISG20 promotes local tumor immunity and contributes to poor survival in human glioma. Oncoimmunol. 2019;8(2):e1534038. doi: 10.1080/2162402X.2018.1534038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2018.1534038</ArticleId><ArticleId IdType="pmc">PMC6343791</ArticleId><ArticleId IdType="pubmed">30713788</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>